P. Futreal

发表

PRDM16s transforms megakaryocyte-erythroid progenitors to acute myeloid leukemia-initiating cells.

P. A. Futreal, Matthew C. Hill, Koichi Takahashi, 2019, Blood.

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

P. A. Futreal, Erika J. Thompson, M. Konopleva, 2018, Nature Communications.

Intratumor Heterogeneity: Seeing the Wood for the Trees

Charles Swanton, Lajos Pusztai, P. A. Futreal, 2012, Science Translational Medicine.

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

P. A. Futreal, Z. Szallasi, N. Matthews, 2012, The New England journal of medicine.

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma

P. A. Futreal, Xin Hu, I. Wistuba, 2021, medRxiv.

The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics

P. A. Futreal, Xin Hu, I. Wistuba, 2021, Nature Communications.

The histologic phenotype of lung cancers may be driven by transcriptomic features rather than genomic characteristics

P. A. Futreal, Xin Hu, I. Wistuba, 2021, bioRxiv.

PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy

P. A. Futreal, L. Donehower, Tajhal Dayaram, 2018, Cell stem cell.

Chromosomal instability confers intrinsic multidrug resistance.

Nicolai J. Birkbak, P. A. Futreal, Z. Szallasi, 2011, Cancer research.

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in AML

P. A. Futreal, J. Dick, M. Minden, 2022, bioRxiv.

Emerging patterns of somatic mutations in cancer

P. A. Futreal, L. Chin, Koichi Takahashi, 2013, Nature Reviews Genetics.

Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association

P. A. Futreal, Y. A. Wang, Jianhua Zhang, 2022, Nature communications.

FusionPathway: Prediction of pathways and therapeutic targets associated with gene fusions in cancer

P. Andrew Futreal, Jianhua Zhang, Chia-Chin Wu, 2018, PLoS Comput. Biol..

Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer

P. A. Futreal, X. Yi, I. Wistuba, 2018, Nature Communications.

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

P. A. Futreal, L. Chin, J. Wargo, 2017, Science Translational Medicine.

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

P. A. Futreal, N. Matthews, I. Varela, 2014, Nature Genetics.

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

Jared C Malke, Julie M Simon, Christine B. Peterson, 2021, Science.

Genomic heterogeneity of multiple synchronous lung cancer

Dongmei Lin, Li Zhang, John V Heymach, 2016, Nature Communications.

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

P. A. Futreal, I. Wistuba, Yamei Chen, 2019, Oncogene.

Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing.

Karl J. Dykema, H. Grabsch, Dachuan Huang, 2011, Cancer research.

Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes

Bin Tean Teh, Niranjan Nagarajan, Denis Bertrand, 2012, Nature Genetics.

Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity

P. A. Futreal, A. Lucas, Xin Hu, 2020, Genome Biology.

Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers

P. A. Futreal, I. Wistuba, S. Swisher, 2020, Journal of thoracic disease.

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

Yu Cao, Yuanqing Ye, Harshad Mahadeshwar, 2014, Science.

Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool

P. A. Futreal, M. Stratton, W. Sung, 2013, Science Translational Medicine.

Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)

P. A. Futreal, Hannah C. Beird, M. Konopleva, 2019, Blood Cancer Journal.

Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma

P. A. Futreal, C. Moskaluk, H. Frierson, 2012, Genes, chromosomes & cancer.

The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma

P. A. Futreal, Hannah C. Beird, A. Lazar, 2022, Nature Communications.

The Androgen Receptor: A Therapeutic Target in Desmoplastic Small Round Cell Sarcoma

P. A. Futreal, Hannah C. Beird, A. Lazar, 2022, bioRxiv.

Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics

Prahlad T. Ram, P. A. Futreal, Jun Yao, 2022, JAMA network open.

Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome

P. A. Futreal, P. Stephens, R. Weber, 2011, Clinical Cancer Research.

State of the Science: An Update on Renal Cell Carcinoma

P. A. Futreal, J. Brugarolas, W. Rathmell, 2012, Molecular Cancer Research.

Germline DNMT3A mutation in familial acute myeloid leukaemia

P. A. Futreal, Hannah C. Beird, M. Estecio, 2020, Epigenetics.

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.

R. Kahnoski, K. Furge, B. Teh, 2010, Cancer research.

Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment

P. A. Futreal, M. Stratton, A. Iafrate, 2007, Clinical Cancer Research.

The human mammary-derived growth inhibitor (MDGI) gene: genomic structure and mutation analysis in human breast tumors.

P. A. Futreal, C. Larsson, P. Tonin, 1996, Genomics.

Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.

P. A. Futreal, R. Deberardinis, J. Huse, 2019, Cancer discovery.

Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer.

P. A. Futreal, I. Wistuba, A. Reuben, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Mark M. Davis, P. A. Futreal, R. Emerson, 2020, Nature Communications.

Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma

P. A. Futreal, Bin Liu, G. Lozano, 2017, Journal of the National Cancer Institute.

Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T‐cell receptor sequencing

P. A. Futreal, X. Yi, Jin Huang, 2023, Molecular oncology.

Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.

J. Roth, I. Wistuba, J. Lee, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multi-modal molecular programs regulate melanoma cell state

P. A. Futreal, M. Morgan, A. G. Robertson, 2022, Nature Communications.

Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.

P. Scheet, I. Wistuba, Y. Yatabe, 2017, Cancer research.

Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS

P. A. Futreal, X. Yi, S. Kopetz, 2019, Modern Pathology.

Multi-site desmoplastic small round cell tumors are genetically related and immune-cold

P. A. Futreal, Hannah C. Beird, A. Lazar, 2022, npj Precision Oncology.

Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer

P. A. Futreal, T. Conrads, A. Sood, 2022, Cancers.

TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

Ryan Emerson, Jaime Rodriguez-Canales, Boris Sepesi, 2017, Cancer discovery.

Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis

P. A. Futreal, Jianhua Zhang, Xingzhi Song, 2018, Oncotarget.

Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer

P. A. Futreal, X. Yi, Wei Wu, 2018, Nature Communications.

Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state

P. A. Futreal, Hannah C. Beird, K. Hunt, 2021, Acta Neuropathologica.

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

M. Ross, J. McQuade, B. Helmink, 2022, Nature.

Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors

P. A. Futreal, M. Wilkerson, T. Conrads, 2022, Journal of translational medicine.

Differing total mRNA expression shapes the molecular and clinical phenotype of cancer

P. A. Futreal, P. Campbell, P. Boutros, 2020, bioRxiv.

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

P. A. Futreal, Erika J. Thompson, N. Navin, 2020, Nature Communications.

Comprehensive molecular characterization of mitochondrial genomes in human cancers

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2017, bioRxiv.

Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer

X. Yi, S. Kopetz, P. A. Futreal, 2020, Cell Death & Disease.

Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression

P. A. Futreal, M. Nykter, T. Speed, 2022, Nature Biotechnology.

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

P. A. Futreal, N. Navin, J. Wargo, 2020, Nature Communications.

Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML)

Erika J. Thompson, M. Konopleva, M. Andreeff, 2018, Blood.

Immuno-genomic landscape of osteosarcoma

P. A. Futreal, Hannah C. Beird, G. Mills, 2020, Nature Communications.

c-kit gene mutations in adenoid cystic carcinoma are rare

P. A. Futreal, C. Moskaluk, H. Frierson, 2010, Modern Pathology.

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

P. A. Futreal, Z. Estrov, H. Kantarjian, 2019, Blood advances.

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.

P. A. Futreal, K. Do, Z. Estrov, 2018, Blood.

Exome sequencing of liver fluke–associated cholangiocarcinoma

Bin Tean Teh, Sopit Wongkham, Choon Kiat Ong, 2012, Nature Genetics.

Patterns of somatic structural variation in human cancer genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature.

Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib

P. A. Futreal, M. Konopleva, H. Kantarjian, 2022, Leukemia.

Genomic Profiling of Multifocal Intrahepatic Cholangiocarcinoma Reveals Intraindividual Concordance of Genetic Alterations.

P. A. Futreal, Ju-Seog Lee, J. Vauthey, 2020, Carcinogenesis.

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

P. A. Futreal, Z. Szallasi, I. Csabai, 2018, Cell.

Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features

P. A. Futreal, P. Scheet, I. Wistuba, 2020, Nature Communications.

A novel Bayesian model for assessing intratumor heterogeneity of tumor infiltrating leukocytes with multi-region gene expression sequencing

Ying Yuan, S. Hubert, Xingzhi Song, 2023, bioRxiv.

Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer

P. A. Futreal, K. Lu, G. Chisholm, 2017, Journal of the National Cancer Institute.

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

P. A. Futreal, J. Dick, M. Minden, 2022, Nature Medicine.

Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network

P. A. Futreal, Daoud M. Meerzaman, S. Gabriel, 2020, Clinical Cancer Research.

Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets

P. A. Futreal, J. Aster, J. Lee, 2020, Clinical Cancer Research.

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer

Jacco, P. A. Futreal, P. Kristel, 2022, Nature Genetics.

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

Mark M. Davis, P. A. Futreal, I. Weissman, 2021, Immunity.

State of the Science: An Update on Renal Cell Carcinoma

J. Brugarolas, W. Rathmell, E. Jonasch, 2012, Molecular Cancer Research.

Review State of the Science : An Update on Renal Cell Carcinoma

P. A. Futreal, J. Brugarolas, W. Rathmell, 2012 .

Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

P. A. Futreal, Jing Wang, I. Wistuba, 2018, Nature Medicine.

Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer

X. Yi, S. Kopetz, Yuhua Gong, 2020, Cell Death & Disease.

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

P. A. Futreal, M. Konopleva, M. Andreeff, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling.

P. A. Futreal, J. McQuade, J. Wargo, 2018, Cancer discovery.

A pre-existing rare PIK 3 CA E 545 K subpopulation confers clinical resistance to MEK plus CDK 4 / 6 inhibition in NRAS melanoma and is dependent on S 6 K 1 signaling

P. A. Futreal, J. McQuade, J. Wargo, 2018 .

Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer

P. A. Futreal, Erika J. Thompson, A. Jazaeri, 2022, Cancers.

High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics

P. A. Futreal, H. Kantarjian, K. Patel, 2018, Genome research.

High-throughput single-cell DNA sequencing of AML tumors with droplet microfluidics

Keith W. Jones, P. A. Futreal, P. Futreal, 2017, bioRxiv.

Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma

Hannah C. Beird, K. Wani, Wei-Lien Wang, 2023, HGG advances.

Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy

P. A. Futreal, X. Yi, K. Ye, 2020, Clinical Cancer Research.

The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma

P. A. Futreal, X. Yi, J. Roth, 2019, Clinical Cancer Research.

Novel MYBL1 Gene Rearrangements with Recurrent MYBL1–NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations

P. A. Futreal, R. Weber, B. Liu, 2015, Clinical Cancer Research.

Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

P. A. Futreal, N. Schultz, J. Ross, 2019, The Journal of clinical investigation.

P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

S. Swisher, J. Heymach, A. Reuben, 2018, Journal of Thoracic Oncology.

Immunogenomic profiling of lung adenocarcinoma reveals high-grade growth patterns are associated with an immunogenic tumor microenvironment

Jianhua, P. A. Futreal, P. Scheet, 2022, medRxiv.

Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics

P. A. Futreal, Jianhua Zhang, L. Beretta, 2021, International journal of molecular sciences.

A computational network approach to identify predictive biomarkers and therapeutic combinations for anti-PD-1 immunotherapy in cancer

Y. A. Wang, Jianhua Zhang, P. A. Futreal, 2020, bioRxiv.

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set

P. A. Futreal, G. Mills, K. Hess, 2016, BMC Medicine.

Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung

Noah A. Kallsen, Shanna A. Peyton, P. A. Futreal, 2019, EBioMedicine.

Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer

P. A. Futreal, Jing Wang, W. Hong, 2018, Modern Pathology.

Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin

P. A. Futreal, Hannah C. Beird, P. Hwu, 2018, Cold Spring Harbor molecular case studies.

Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes

A. Reuben, C. Behrens, J. Fujimoto, 2024, Cancer innovation.

Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups

P. A. Futreal, A. Sood, Jianhua Zhang, 2021, iScience.

T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid

P. A. Futreal, Hannah C. Beird, Koichi Takahashi, 2020, Leukemia.

Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment

P. A. Futreal, Xin Hu, I. Wistuba, 2020, Clinical Cancer Research.

K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.

A. Berchuck, R. Bentley, S. Robboy, 2001, Gynecologic oncology.

Targeting IL-11R/EZH2 signaling axis as a therapeutic strategy for osteosarcoma lung metastases

Hannah C. Beird, Valerae O. Lewis, Eswaran Devarajan, 2024, Discover oncology.